Precigen, Inc. (NASDAQ:PGEN) Given Average Rating of “Moderate Buy” by Brokerages

Precigen, Inc. (NASDAQ:PGEN) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $7.00.

A number of equities analysts have recently weighed in on PGEN shares. HC Wainwright lowered their price target on shares of Precigen from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. JMP Securities lowered their price objective on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 15th. Finally, StockNews.com raised shares of Precigen to a “sell” rating in a research note on Thursday, August 1st.

Precigen Stock Up 1.3 %

NASDAQ:PGEN opened at $0.82 on Wednesday. Precigen has a fifty-two week low of $0.79 and a fifty-two week high of $1.93. The stock has a market cap of $208.07 million, a PE ratio of -1.52 and a beta of 1.68. The firm’s fifty day simple moving average is $0.95 and its 200-day simple moving average is $1.27.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Precigen had a negative return on equity of 90.99% and a negative net margin of 3,084.55%. The company had revenue of $0.72 million for the quarter, compared to analyst estimates of $1.28 million. Equities analysts anticipate that Precigen will post -0.44 earnings per share for the current year.

Insider Activity at Precigen

In other news, SVP Jeffrey Thomas Perez purchased 58,823 shares of the firm’s stock in a transaction on Friday, August 9th. The shares were bought at an average cost of $0.85 per share, with a total value of $49,999.55. Following the purchase, the senior vice president now directly owns 743,097 shares of the company’s stock, valued at approximately $631,632.45. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 44.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Precigen

Hedge funds have recently modified their holdings of the company. Traphagen Investment Advisors LLC acquired a new stake in shares of Precigen during the 3rd quarter worth about $29,000. EntryPoint Capital LLC purchased a new position in shares of Precigen during the 1st quarter worth about $31,000. SG Americas Securities LLC lifted its holdings in shares of Precigen by 44.2% during the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 13,823 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Precigen by 86.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 25,681 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in shares of Precigen by 56.7% during the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares during the period. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.